Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMGN.MX
STRONG BUYAmgen Inc. · Healthcare · United States · $192.8B · Avg Vol: $2K/d
COMPANY DESCRIPTION
Amgen Inc. is a pioneer in biotechnology, discovering, developing, and manufacturing innovative human therapeutics across oncology, cardiovascular, and inflammatory diseases. The company's competitive moat is sustained by a robust portfolio of biologic drugs, a deep clinical pipeline, and advanced manufacturing capabilities that are difficult for generic competitors to replicate. Amgen maintains a leading market position, supported by strong intellectual property protection and high barriers to entry in biosimilars.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.3B | 28.2B | 33.4B | 36.8B | 11.8% | 37.2B | 37.8B | 38.7B | 2.6% |
| EPS | 12.18 | 12.56 | 7.62 | 14.33 | 5.6% | 14.38 | — | — | — |
| Shares | 534.0M | 535.4M | 537.0M | 538.8M | +0.9% | 539.7M | — | — | — |
| Debt | 38.9B | 64.6B | 60.1B | 54.6B | 11.9% | 57.3B | — | — | — |
| Equity | 3.7B | 6.2B | 5.9B | 8.7B | 33.2% | — | — | — | — |
| Op CF | 9.7B | 8.5B | 11.5B | 10.0B | 0.8% | 10.8B | — | — | — |
| Inv CF | -6.0B | -26.2B | -1.0B | -1.9B | — | — | — | — | — |
| Fin CF | -4.0B | 21.0B | -9.4B | -10.9B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMGN.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMGN.MX | Amgen Inc.(you) | $192.8B | 96 | STRONG BUY |
| GILD | Gilead Sciences, Inc. | $158.8B | 95 | STRONG BUY |
| PFE.MX | Pfizer Inc. | $137.8B | 95 | STRONG BUY |
| NVON.MX | Novo Nordisk A/S | $212.5B | 90 | STRONG BUY |
| ROP.SW | Roche Holding AG | $323.7B | 97 | STRONG BUY |
| MRK.MX | Merck & Co., Inc. | $316.3B | 98 | STRONG BUY |
| BMY | Bristol-Myers Squibb Company | $117.5B | 99 | STRONG BUY |
| GSK | GSK plc | $105.2B | 95 | STRONG BUY |
| SNY | Sanofi | $102.8B | 96 | STRONG BUY |
| NOVN.SW | Novartis AG | $297.7B | 85 | STRONG BUY |
Peer medians: ROE 2.7% · P/E 22.8x · Gross margin 47.5%